Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Head and Neck Neoplasms 2Gliosarcoma 2Glioma 2Colorectal Neoplasms 2Breast Neoplasms 2Brain Neoplasms 2Supratentorial Neoplasms 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Bronchiolitis Obliterans Syndrome 1Astrocytoma 1

Interventions

Saline Solution 3Ropivacaine 2Propofol 2Morphine 2Mannitol 2Dexmedetomidine 2lonafarnib 1dexketoprofen trometamol 1Temozolomide 1Stem Cell Transplantation 1Remifentanil 1Long-Term Synaptic Depression 1Lidocaine 1HES 130-0.4 1Epinephrine 1Dexamethasone 1Desflurane 1Bupivacaine 1Analgesics, Opioid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Supratentorial Neoplasms × lonafarnib × Clear all
NCT00102648 2024-10-17

Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
34 enrolled
CNSSarcoma

Glioblastoma, Supratentorial Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡